209 related articles for article (PubMed ID: 21681684)
1. Passive immunization with allergen-specific antibodies.
Flicker S; Gadermaier E; Madritsch C; Valenta R
Curr Top Microbiol Immunol; 2011; 352():141-59. PubMed ID: 21681684
[TBL] [Abstract][Full Text] [Related]
2. IgE-mediated allergen presentation and blocking antibodies: regulation of T-cell activation in allergy.
van Neerven RJ; Knol EF; Ejrnaes A; Würtzen PA
Int Arch Allergy Immunol; 2006; 141(2):119-29. PubMed ID: 16864979
[TBL] [Abstract][Full Text] [Related]
3. Renaissance of the blocking antibody concept in type I allergy.
Flicker S; Valenta R
Int Arch Allergy Immunol; 2003 Sep; 132(1):13-24. PubMed ID: 14555854
[TBL] [Abstract][Full Text] [Related]
4. Passive immunization with allergen-specific IgG antibodies for treatment and prevention of allergy.
Flicker S; Linhart B; Wild C; Wiedermann U; Valenta R
Immunobiology; 2013 Jun; 218(6):884-91. PubMed ID: 23182706
[TBL] [Abstract][Full Text] [Related]
5. Cloning allergen-specific antibody fragments (Fabs); tools for allergen standardization and therapy of type I allergy.
Valenta R; Steinberger P; Laffer S; Dolecek C; Wiedemann P; Flicker S; Kraft D
Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 1997; (91):222-9. PubMed ID: 9383913
[TBL] [Abstract][Full Text] [Related]
6. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies.
Mothes N; Heinzkill M; Drachenberg KJ; Sperr WR; Krauth MT; Majlesi Y; Semper H; Valent P; Niederberger V; Kraft D; Valenta R
Clin Exp Allergy; 2003 Sep; 33(9):1198-208. PubMed ID: 12956739
[TBL] [Abstract][Full Text] [Related]
7. Allergen-Specific Antibodies Regulate Secondary Allergen-Specific Immune Responses.
Eckl-Dorna J; Villazala-Merino S; Linhart B; Karaulov AV; Zhernov Y; Khaitov M; Niederberger-Leppin V; Valenta R
Front Immunol; 2018; 9():3131. PubMed ID: 30705676
[TBL] [Abstract][Full Text] [Related]
8. Recombinant allergen molecules: tools to study effector cell activation.
Valenta R; Kraft D
Immunol Rev; 2001 Feb; 179():119-27. PubMed ID: 11292015
[TBL] [Abstract][Full Text] [Related]
9. Immunization with purified natural and recombinant allergens induces mouse IgG1 antibodies that recognize similar epitopes as human IgE and inhibit the human IgE-allergen interaction and allergen-induced basophil degranulation.
Vrtala S; Ball T; Spitzauer S; Pandjaitan B; Suphioglu C; Knox B; Sperr WR; Valent P; Kraft D; Valenta R
J Immunol; 1998 Jun; 160(12):6137-44. PubMed ID: 9637531
[TBL] [Abstract][Full Text] [Related]
10. Reducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination.
Ball T; Linhart B; Sonneck K; Blatt K; Herrmann H; Valent P; Stoecklinger A; Lupinek C; Thalhamer J; Fedorov AA; Almo SC; Valenta R
Allergy; 2009 Apr; 64(4):569-80. PubMed ID: 19243361
[TBL] [Abstract][Full Text] [Related]
11. Sensitization of skin mast cells with IgE antibodies to Culicoides allergens occurs frequently in clinically healthy horses.
Wagner B; Miller WH; Erb HN; Lunn DP; Antczak DF
Vet Immunol Immunopathol; 2009 Nov; 132(1):53-61. PubMed ID: 19836083
[TBL] [Abstract][Full Text] [Related]
12. Blocking antibodies induced by immunization with a hypoallergenic parvalbumin mutant reduce allergic symptoms in a mouse model of fish allergy.
Freidl R; Gstoettner A; Baranyi U; Swoboda I; Stolz F; Focke-Tejkl M; Wekerle T; van Ree R; Valenta R; Linhart B
J Allergy Clin Immunol; 2017 Jun; 139(6):1897-1905.e1. PubMed ID: 27876628
[TBL] [Abstract][Full Text] [Related]
13. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation.
van Neerven RJ; Wikborg T; Lund G; Jacobsen B; Brinch-Nielsen A; Arnved J; Ipsen H
J Immunol; 1999 Sep; 163(5):2944-52. PubMed ID: 10453043
[TBL] [Abstract][Full Text] [Related]
14. Facilitated antigen presentation and its inhibition by blocking IgG antibodies depends on IgE repertoire complexity.
Holm J; Willumsen N; Würtzen PA; Christensen LH; Lund K
J Allergy Clin Immunol; 2011 Apr; 127(4):1029-37. PubMed ID: 21377718
[TBL] [Abstract][Full Text] [Related]
15. Decline of Ves v 5-specific blocking capacity in wasp venom-allergic patients after stopping allergen immunotherapy.
Möbs C; Müller J; Rudzio A; Pickert J; Blank S; Jakob T; Spillner E; Pfützner W
Allergy; 2015 Jun; 70(6):715-9. PubMed ID: 25753563
[TBL] [Abstract][Full Text] [Related]
16. Allergen-specific polyclonal antibodies reduce allergic disease in a mouse model of allergic asthma.
Moerch U; Haahr Hansen M; Vest Hansen NJ; Rasmussen LK; Oleksiewicz MB; Frandsen TP; Haurum JS; Bregenholt S
Int Arch Allergy Immunol; 2006; 140(3):261-9. PubMed ID: 16699287
[TBL] [Abstract][Full Text] [Related]
17. [Bee venom allergy (a model of an IgE-mediated immediate-type allergy)].
Jarisch R
Wien Klin Wochenschr Suppl; 1980; 122():3-27. PubMed ID: 7013279
[No Abstract] [Full Text] [Related]
18. Fel d1 Blocking Antibodies: A Novel Method to Reduce IgE-Mediated Allergy to Cats.
Satyaraj E; Sun P; Sherrill S
J Immunol Res; 2021; 2021():5545173. PubMed ID: 34250096
[TBL] [Abstract][Full Text] [Related]
19. The role of allergen-specific IgE, IgG and IgA in allergic disease.
Shamji MH; Valenta R; Jardetzky T; Verhasselt V; Durham SR; Würtzen PA; van Neerven RJJ
Allergy; 2021 Dec; 76(12):3627-3641. PubMed ID: 33999439
[TBL] [Abstract][Full Text] [Related]
20. Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation.
Gadermaier E; Staikuniene J; Scheiblhofer S; Thalhamer J; Kundi M; Westritschnig K; Swoboda I; Flicker S; Valenta R
Allergy; 2011 Sep; 66(9):1174-82. PubMed ID: 21480924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
